TrialDexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Trial details
- Registry ID
- NCT04268303
- Phase
- Phase 3
BTAIQ
BioXcel Therapeutics Inc
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceDexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
Trial details
- Registry ID
- NCT04276883
- Phase
- Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
Trial details
- Registry ID
- NCT05271552
- Phase
- Phase 3
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
Trial details
- Registry ID
- NCT05276830
- Phase
- Phase 2
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Trial details
- Registry ID
- NCT05658510
- Phase
- Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
Trial details
- Registry ID
- NCT05665088
- Phase
- Phase 3
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
Trial details
- Registry ID
- NCT07116694
- Phase
- Phase 2
Latest recorded trial changes
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
NCT07116694 · BioXcel Therapeutics Inc
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
30 participants (planned)
+ After
33 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Oct 2025
+ After
7 Oct 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
NCT05271552 · BioXcel Therapeutics Inc
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Absolute change from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total score
+ After
Measure: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation